870295 | DSPE-RGD Lipid
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
DSPE-RGD Lipid
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)
DSPE is a fully saturated phospholipid consisting of 18 carbon atoms, frequently employed in the creation of liposomes. Phospholipid Polyethylene Glycol RGD (DSPE-PEG-RGD) finds versatile applications in micelles and vesicles, functioning for both passive and active targeting, along with drug delivery. The integration of Polyethylene Glycol (PEG) with DSPE renders it hydrophilic, facilitating applications in drug delivery, gene transfection, and biomolecular modification. The introduction of PEG to the phospholipid notably enhances the durability and circulation lifespan of encapsulated medications.
DSPE-RGD lipid represents a lipid compound suitable for incorporation into liposomes—microscopic, spherical structures composed of a double layer of lipids. DSPE-RGD introduces a more advanced iteration, having undergone modification with the RGD peptide sequence.
The RGD peptide sequence, an acronym for arginine-glycine-aspartic acid, is a short string of amino acids with the capacity to attach to integrin receptors situated on cell surfaces. These integrin receptors are present in various cell types, including cancer cells and those lining blood vessels.
Importantly, DSPE-RGD lipid is biocompatible, thereby minimizing the likelihood of triggering immune reactions or significant bodily toxicity.
Research has demonstrated that DSPE-RGD enhances the concentration of drugs within tumor tissue, thereby enhancing the efficacy of chemotherapy and other cancer therapies. Additionally, it has been observed to diminish the adverse effects of these treatments on normal cells. Through the precisely targeted mechanism of DSPE-RGD liposomes, drugs can be selectively transported to tumor tissue, thereby mitigating the potential harm to healthy cells.
DSPE-RGD holds promise in yet another field: addressing cardiovascular illnesses. The RGD peptide sequence not only has the potential to zero in on integrin receptors present on blood vessel cells' surfaces but also presents the opportunity for precise drug delivery to afflicted vessels. This targeted approach could foster healing and decrease the likelihood of complications such as heart attacks or strokes.
Moreover, DSPE-RGD could extend its usefulness to the realm of inflammatory conditions, including rheumatoid arthritis. As inflammatory cells also exhibit integrin receptors, they become a feasible target for DSPE-RGD liposomes. By conveying anti-inflammatory agents directly to these cells, DSPE-RGD could contribute to diminishing inflammation and alleviating associated symptoms.
Avanti Research offers this lipopeptide in 1 mg powder packaging.
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozChen CW, Lu DW, Yeh MK, Shiau CY, Chiang CH. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine. 2011;6:2567-80. doi: 10.2147/IJN.S24447. Epub 2011 Oct 26. PMID: 22128247; PMCID: PMC3225218.
PubMed ID: 22128247Cao Y, Zhou Y, Zhuang Q, Cui L, Xu X, Xu R, He X. Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer. Int J Clin Exp Med. 2015 Aug 15;8(8):12182-91. PMID: 26550128; PMCID: PMC4612813.
PubMed ID: 26550128- Certificate of Analysis (Lot No. 870295P-1MG-A-010 and 6184PGA010)
- Certificate of Analysis (Lot No. 870295P-1MG-B-010 and 6184PGB010)
- Certificate of Analysis (Lot No. 870295P-1MG-C-010 and 6184PGC010)
- Certificate of Analysis (Lot No. 870295P-1MG-D-010 and 6184PGD010)
- Certificate of Analysis (Lot No. 870295P-1MG-A-011 and 6184PGA011)
- Certificate of Analysis (Lot No. 870295P-1MG-B-011 and 6184PGB011)
- Certificate of Analysis (Lot No. 870295P-1MG-D-011 and 6184PGD011)
- Certificate of Analysis (Lot No. 870295P-1MG-A-012 and 6184PGA012)
- Certificate of Analysis (Lot No. 870295P-1MG-B-012 and 6184PGB012)
- Certificate of Analysis (Lot No. 870295P-1MG-C-012 and 6184PGC012)
